Dr Hudis presents, at a press conference at ASCO 2015, three key initiatives designed to advance precision medicine:

The National Cancer Institute-MATCH (NCI-MATCH) trial, co-led by the ECOG-ACRIN Cancer Research Group, which is designed to seek evidence that treating patients based on their tumours' molecular profile, rather than by tumour type, may have clinical benefit

The Targeted Agent and Profiling Utilization Registry (TAPUR), the first ASCO-led clinical trial, which will offer patients with advanced cancer access to molecularly-targeted cancer drugs and collect "real-world" data on clinical outcomes to help learn the best uses of these drugs outside of indications approved by the Food and Drug Administration

CancerLinQ, ASCO's groundbreaking health information technology initiative to achieve higher quality, higher value